CVS Health (NYSE:CVS – Get Free Report) had its price target lifted by investment analysts at Robert W. Baird from $92.00 to $94.00 in a research note issued on Wednesday, Marketbeat reports. The firm presently has an “outperform” rating on the pharmacy operator’s stock. Robert W. Baird’s price objective would indicate a potential upside of 22.55% from the stock’s current price.
CVS has been the subject of a number of other reports. Argus decreased their target price on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $91.00 to $94.00 in a research report on Thursday, March 12th. Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Finally, Piper Sandler decreased their target price on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research report on Tuesday, March 31st. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.05.
Read Our Latest Research Report on CVS Health
CVS Health Stock Performance
CVS Health (NYSE:CVS – Get Free Report) last issued its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period in the previous year, the company posted $1.19 EPS. The firm’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts expect that CVS Health will post 5.89 earnings per share for the current year.
Institutional Trading of CVS Health
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. National Pension Service raised its holdings in CVS Health by 3.1% during the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after acquiring an additional 119,189 shares during the period. Kingsview Wealth Management LLC raised its holdings in CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after acquiring an additional 79,340 shares during the period. AE Wealth Management LLC raised its holdings in CVS Health by 6.2% during the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after acquiring an additional 14,983 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in CVS Health by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after acquiring an additional 22,653 shares during the period. Finally, Alpha Omega Wealth Management LLC raised its holdings in CVS Health by 12.3% during the 3rd quarter. Alpha Omega Wealth Management LLC now owns 149,902 shares of the pharmacy operator’s stock valued at $11,301,000 after acquiring an additional 16,418 shares during the period. 80.66% of the stock is owned by institutional investors.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Robert W. Baird raised its price target on CVS to $94 and kept an “outperform” rating — this analyst upgrade supports upside expectations and likely helped buying interest. Baird price target raise
- Positive Sentiment: Television/commentator coverage (Jim Cramer) highlighted a structural advantage for CVS, boosting investor sentiment and media-driven buying momentum. Jim Cramer Shares Big Advantage For CVS Health Corporation (CVS)
- Neutral Sentiment: Comparisons of retail pharmacy pricing (GoodRx vs. CVS vs. Costco) are in the press; these stories affect competitive perception but are unlikely to move fundamentals immediately. GoodRx vs. CVS vs. Costco: Where Retirees Save the Most on Prescriptions
- Neutral Sentiment: Analyst and retail‑flow summaries (Zacks, MarketWatch) show elevated attention and some short‑term underperformance vs. peers — signals of redistribution/volatility rather than a clear directional catalyst. Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
- Negative Sentiment: More than 500 drivers and warehouse workers at CVS’s Fredericksburg, VA distribution center have authorized a strike (vote overwhelmingly to strike; contract expires April 30). A May 1 walkout could disrupt logistics, raise costs and pressure short‑term service metrics. CVS distribution center workers plan to go on strike
- Negative Sentiment: TheStreet reports a CVS division has entered a Chapter 11 liquidation sale — a potential multi‑hundred‑million to billion‑dollar charge that can weigh on earnings and investor sentiment until resolved. CVS division enters Chapter 11 liquidation sale
- Negative Sentiment: Investors remain sensitive to PBM legal and regulatory risk — recent commentary links a pullback to class‑action allegations and heightened regulator scrutiny of PBM practices, which can pressure valuation multiple and future PBM margins. CVS slides 3.1% as investors refocus on PBM legal/regulatory overhang after recent sector optimism
- Negative Sentiment: Ongoing governance friction and settlement talks tied to insulin pricing and shareholder proposals add policy and reputational uncertainty ahead of the May annual meeting — another near‑term headline risk. How Investors Are Reacting To CVS Health (CVS) Insulin Case Settlement Talks And Shareholder Rights Clash
About CVS Health
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Further Reading
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
